Calidi Biotherapeutics (CLDI) Depreciation & Amortization (CF) (2022 - 2026)
Calidi Biotherapeutics (CLDI) posted quarterly Depreciation & Amortization (CF) of $1.4 million for Q4 2025, up 243.77% year-over-year from $393000.0 in Q4 2024, and up 1251.0% quarter-over-quarter from $100000.0 in Q3 2025.
Calidi Biotherapeutics (CLDI) Depreciation & Amortization (CF) (2022 - 2026) Analysis & Trends
Calidi Biotherapeutics' Depreciation & Amortization (CF) history runs 4 years deep, the most recent figure standing at $1.4 million for Q4 2025.
- In Q4 2025, Depreciation & Amortization (CF) rose 243.77% year-over-year to $1.4 million; the TTM figure through Dec 2025 stood at $1.6 million (up 136.94% YoY), while the FY2025 annual figure was $1.7 million, up 7.56% from the prior year.
- Depreciation & Amortization (CF) for Q4 2025 stood at $1.4 million, up from $100000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $1.4 million in Q4 2025, with the low at $91000.0 in Q1 2025.
- The 4-year median for Depreciation & Amortization (CF) is $100000.0 (2022), against an average of $208571.4.
- The sharpest annual moves came in 2024 and 2025: Depreciation & Amortization (CF) jumped 327.17% in 2024, then dropped 9.0% in 2025.
- Calidi Biotherapeutics' Depreciation & Amortization (CF) stood at $100000.0 in 2022, then slipped by 8.0% to $92000.0 in 2023, then surged by 327.17% to $393000.0 in 2024, then surged by 243.77% to $1.4 million in 2025.
- Business Quant data shows CLDI's Depreciation & Amortization (CF) at $1.4 million in Q4 2025, $100000.0 in Q3 2025, and $100000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Calidi Biotherapeutics | 1.88 Mn | -2.22 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 100,000.00 |
| Jun 30, 2026 | 100,000.00 |
| Dec 31, 2025 | 1.35 Mn |
| Dec 31, 2025 | 1.35 Mn |
| Sep 30, 2025 | 100,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Mar 31, 2025 | 91,000.00 |
| Mar 31, 2025 | 91,000.00 |
| Dec 31, 2024 | 393,000.00 |
| Dec 31, 2024 | 393,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Mar 31, 2024 | 100,000.00 |
| Mar 31, 2024 | 100,000.00 |
| Dec 31, 2023 | 92,000.00 |
| Dec 31, 2023 | 92,000.00 |